Back to Search
JACOB LALEZARI, M.D.
M.D.
Internal Medicine Physician
NPI: 1124173554Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G61660(CA)
Research & Publications (20)
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
PMID 18266604·J Infect Dis·2008
3-trial
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
PMID 18507525·AIDS Res Hum Retroviruses·2008
4-observational
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
PMID 17491001·J Antimicrob Chemother·2007
3-trial
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
PMID 15747252·J Infect Dis·2005
3-trial
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
PMID 16135896·AIDS·2005
4-observational
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
PMID 12765160·AIDS Read·2003
8-other
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
PMID 14518696·Antivir Ther·2003
3-trial
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
PMID 12957192·J Clin Virol·2003
3-trial
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
PMID 12637625·N Engl J Med·2003
3-trial
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
PMID 12646792·AIDS·2003
3-trial
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
PMID 12183255·Antimicrob Agents Chemother·2002
3-trial
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
PMID 12138345·J Acquir Immune Defic Syndr·2002
3-trial
High dose oral ganciclovir treatment for cytomegalovirus retinitis.
PMID 11744430·J Clin Virol·2002
3-trial
Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.
PMID 11176734·Arch Intern Med·2001
8-other
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.
PMID 19219022·Nat Med·2009
3-trial
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
PMID 18279104·J Interferon Cytokine Res·2008
3-trial
Maraviroc for previously treated patients with R5 HIV-1 infection.
PMID 18832244·N Engl J Med·2008
3-trial
Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection.
PMID 18315507·J Altern Complement Med·2008
4-observational
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
PMID 18433307·Clin Infect Dis·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2300 SUTTER ST
SAN FRANCISCO, CA 94115 - Phone
- (415) 353-0800
Quick Facts
- NPI
- 1124173554
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile